Remdesivir : Effectiveness and Safety in Hospitalized Patients with COVID-19 (ReEs-COVID-19)-Analysis of Data from Daily Practice
Remdesivir was the first antiviral approved for treating COVID-19. We investigated its patterns of use, effectiveness and safety in clinical practice in Greece. This is a retrospective observational study of hospitalized adults who received remdesivir for COVID-19 in September 2020-February 2021. The main endpoints were the time to recovery (hospital discharge within 30 days from admission) and safety. The "early" (remdesivir initiation within 24 h since hospitalization) and "deferred" (remdesivir initiation later on) groups were compared. One thousand and four patients (60.6% male, mean age 61 years, 74.3% with severe disease, 70.9% with ≥1 comorbidities) were included, and 75.9% of them were on a 5-day regimen, and 86.8% were in the early group. Among those with a baseline mild/moderate disease, the median (95% CI) time to recovery was 8 (7-9) and 12 (11-14) days for the early and deferred groups, respectively (p < 0.001). The corresponding estimates for those with a severe disease were 10 (9-10) and 13 (11-15) days, respectively (p = 0.028). After remdesivir initiation, increased serum transaminases and an acute kidney injury were observed in 6.9% and 2.1%, respectively. Nine (0.9%) patients discontinued the treatment due to adverse events. The effectiveness of remdesivir was increased when it was taken within 24 h since admission regardless of the disease severity. Remdesivir's safety profile is similar to that described in clinical trials and other real-world cohorts.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Microorganisms - 11(2023), 8 vom: 03. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pantazis, Nikos [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 29.08.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/microorganisms11081998 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361287402 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361287402 | ||
| 003 | DE-627 | ||
| 005 | 20231226084825.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/microorganisms11081998 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1204.xml |
| 035 | |a (DE-627)NLM361287402 | ||
| 035 | |a (NLM)37630558 | ||
| 035 | |a (PII)1998 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pantazis, Nikos |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Remdesivir |b Effectiveness and Safety in Hospitalized Patients with COVID-19 (ReEs-COVID-19)-Analysis of Data from Daily Practice |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 29.08.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Remdesivir was the first antiviral approved for treating COVID-19. We investigated its patterns of use, effectiveness and safety in clinical practice in Greece. This is a retrospective observational study of hospitalized adults who received remdesivir for COVID-19 in September 2020-February 2021. The main endpoints were the time to recovery (hospital discharge within 30 days from admission) and safety. The "early" (remdesivir initiation within 24 h since hospitalization) and "deferred" (remdesivir initiation later on) groups were compared. One thousand and four patients (60.6% male, mean age 61 years, 74.3% with severe disease, 70.9% with ≥1 comorbidities) were included, and 75.9% of them were on a 5-day regimen, and 86.8% were in the early group. Among those with a baseline mild/moderate disease, the median (95% CI) time to recovery was 8 (7-9) and 12 (11-14) days for the early and deferred groups, respectively (p < 0.001). The corresponding estimates for those with a severe disease were 10 (9-10) and 13 (11-15) days, respectively (p = 0.028). After remdesivir initiation, increased serum transaminases and an acute kidney injury were observed in 6.9% and 2.1%, respectively. Nine (0.9%) patients discontinued the treatment due to adverse events. The effectiveness of remdesivir was increased when it was taken within 24 h since admission regardless of the disease severity. Remdesivir's safety profile is similar to that described in clinical trials and other real-world cohorts | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a effectiveness | |
| 650 | 4 | |a hospitalized patients | |
| 650 | 4 | |a remdesivir | |
| 650 | 4 | |a safety | |
| 700 | 1 | |a Pechlivanidou, Evmorfia |e verfasserin |4 aut | |
| 700 | 1 | |a Antoniadou, Anastasia |e verfasserin |4 aut | |
| 700 | 1 | |a Akinosoglou, Karolina |e verfasserin |4 aut | |
| 700 | 1 | |a Kalomenidis, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a Poulakou, Garyfallia |e verfasserin |4 aut | |
| 700 | 1 | |a Milionis, Haralampos |e verfasserin |4 aut | |
| 700 | 1 | |a Panagopoulos, Periklis |e verfasserin |4 aut | |
| 700 | 1 | |a Marangos, Markos |e verfasserin |4 aut | |
| 700 | 1 | |a Katsarolis, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a Kazakou, Pinelopi |e verfasserin |4 aut | |
| 700 | 1 | |a Dimakopoulou, Vasiliki |e verfasserin |4 aut | |
| 700 | 1 | |a Chaliasou, Anna-Louiza |e verfasserin |4 aut | |
| 700 | 1 | |a Rapti, Vasiliki |e verfasserin |4 aut | |
| 700 | 1 | |a Christaki, Eirini |e verfasserin |4 aut | |
| 700 | 1 | |a Liontos, Angelos |e verfasserin |4 aut | |
| 700 | 1 | |a Petrakis, Vasileios |e verfasserin |4 aut | |
| 700 | 1 | |a Schinas, Georgios |e verfasserin |4 aut | |
| 700 | 1 | |a Biros, Dimitrios |e verfasserin |4 aut | |
| 700 | 1 | |a Rimpa, Maria-Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Touloumi, Giota |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Microorganisms |d 2013 |g 11(2023), 8 vom: 03. Aug. |w (DE-627)NLM247050237 |x 2076-2607 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2023 |g number:8 |g day:03 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/microorganisms11081998 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2023 |e 8 |b 03 |c 08 | ||